# Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

> **NCT00259129** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 53 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT00259129
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-02
- **Final completion:** 2008-03
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259129, "Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00259129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*